Introduction {#s1}
============

Peripheral neuropathy is a syndrome characterized by loss of sensation, muscle weakness and atrophy, loss of tendon reflexes, and/or abnormal vascular motion as a clinical manifestation, either alone or in any combination. Drugs, especially for anti-tumor drugs, are one of the common pathogenic factors for the disease ([@B1]--[@B10]). During the course of anti-tumor therapy, whether it is chemotherapy or targeted therapy drugs ([@B1]--[@B5]), peripheral neuropathy is often reported as a drug side effect ([@B1]--[@B10]). Although reports of death due to peripheral neuropathy were rare, it seriously affected the quality of life for patients with malignant tumors ([@B8]--[@B10]). Therefore, peripheral neuropathy caused by anti-tumor drugs had increasingly attracted the attention of clinical doctors ([@B11]--[@B13]).

As a new targeted anti-tumor drug, PD-1/PD-L1 inhibitors have achieved satisfactory clinical efficacy for the treatment of solid tumors, either alone or in combination ([@B14]--[@B29]). With the increasing clinical applications, more and more drug-related side toxicity effects had been reported, and peripheral neuropathy was one of them ([@B14]--[@B29]). Because of the low incidence of peripheral neuropathy, we were unable to determine the association between its incidence risk and PD-1/PD-L1 inhibitors. Some chemotherapeutic drugs, such as paclitaxel, might cause delayed peripheral neuropathy ([@B12], [@B13]). It was impossible for us to identify the association between the incidence risk of peripheral neuropathy and PD-1/PD-L1 inhibitors when they were used in combination with other anti-tumor drugs or prescribed as a second-line treatment after chemotherapy ([@B14]--[@B30]).

For drug-induced peripheral neuropathy, stopping the drug remained to be the primary treatment method ([@B1]--[@B10]). However, for patients with malignant tumors, when severe drug side effects were encountered ([@B12], [@B13]), careful consideration for stopping the drug should be taken into account. Because of the sudden stop of anti-tumor treatment, it was very likely to cause rapid progression of the tumor. When PD-1/PD-L1 inhibitors were used in combination with chemotherapy, it was particularly important to determine the cause of peripheral neuropathy and then decide which drug to be discontinued ([@B15]--[@B18]).

To solve the above problems and clarify the association between incidence risk of peripheral neuropathy and PD-1/PD-L1 inhibitors, we designed this meta-analysis.

Methods {#s2}
=======

The process of the meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines ([@B31]).

Types of Enrolled Studies
-------------------------

According to the research design, the selected clinical studies must meet the following criteria: (1) Randomized controlled clinical trials would be prioritized, (2) PD-1/PD-L1 inhibitor was prescribed for at least one group of participants, (3)The control group was an anti-tumor drug or PD-1/PD-L1 in combination with an anti-tumor drug rather than a placebo, (4) Participants were diagnosed with solid malignant tumors rather than hematological malignancy, (5) Data on peripheral neuropathy were reported in the study, (6) the enrolled study was published in English.

Search Strategy
---------------

Original articles including PD1/PD-L1 inhibitor regimens for solid tumor patients were verified by a systematic search of PubMed. The reported date of the results was limited from Jan 22, 2013 to May 31, 2019. The following subject terms would be used in the literature search process: "cancer," "tumor," "PD1/PD-L1," "nivolumab," "Opdivo," "pembrolizumab," "Keytruda," "Imfinzi,","MK-3475," "atezolizumab," "Tecentriq," "MPDL3280A," "avelumab," "Bavencio," "durvalumab," "BMS-963558." Studies limited in human beings, shown in full text, abstract, or poster form, were selected three investigators (Shuisheng Zhang, Yi Zhao, Qingshan Zhu) were appointed to check eligibility and duplicate independently by screening titles and abstracts of relevant studies. If data on peripheral neuropathy had not been reported, we would contact the corresponding author of the article to verify it again, or it would be precluded from the meta-analysis. The basic characteristics information included in the study would be summarized in [Table 1](#T1){ref-type="table"}.

###### 

Basic characteristics of the included studies.

  **No**.   **Study name**                 **Drug name**   **Drug type**   **Treatment regimen**                                                             **Number of evaluable patients**   **Peripheral neuropathy**   **Previous therapy**   **Phase**   **Randomized controlled trial (RCT)**   **Tumor type**
  --------- ------------------------------ --------------- --------------- --------------------------------------------------------------------------------- ---------------------------------- --------------------------- ---------------------- ----------- --------------------------------------- ----------------------------------------------------------
  1         Cohen et al. ([@B14])          Pembrolizumab   PD-1            Pembrolizumab vs. (Methotrexate, Docetaxel, or Cetuximab)                         480                                7                           Platinum-based         III         RCT                                     Head-and-neck squamous cell carcinoma
  2         Schmid et al. ([@B15])         Atezolizumab    PD-L1           Atezolizumab + Nab-paclitaxel vs. Placebo + Nab-paclitaxel                        890                                195                         NO                     III         RCT                                     Advanced Triple-Negative Breast Cancer (BC)
  3         Horn et al. ([@B16])           Atezolizumab    PD-L1           Atezolizumab + Carboplatin + Etoposide vs. Placebo + Carboplatin + Etoposide      394                                6                           NO                     III         RCT                                     SCLC
  4         Socinski et al. ([@B17])       Atezolizumab    PD-L1           Atezolizumab + BCP vs. BCP                                                        787                                274                         NO                     III         RCT                                     Metastatic non squamous NSCLC
  5         Paz-Ares et al. ([@B18])       Pembrolizumab   PD-1            Pembrolizumab + Carboplatin + Paclitaxel vs. Placebo + Carboplatin + Paclitaxel   558                                102                         NO                     III         RCT                                     Metastatic squamous NSCLC
  6         Shitara et al. ([@B19])        Pembrolizumab   PD-1            Pembrolizumab vs. Paclitaxel                                                      570                                41                          YES                    III         RCT                                     Advanced gastric or gastro-oesophageal junction cancer
  7         Powles et al. ([@B20])         Atezolizumab    PD-L1           Atezolizumab vs. Chemotherapy                                                     1,128                              53                          Platinum-based         III         RCT                                     Locally advanced or metastatic urothelial carcinoma (UC)
  8         Hida et al. ([@B21])           Atezolizumab    PD-L1           Atezolizumab vs. Docetaxel                                                        101                                14                          Platinum-based         III         RCT                                     Locally advanced/metastatic NSCLC
  9         Bellmunt et al. ([@B22])       Pembrolizumab   PD-1            Pembrolizumab vs. Chemotherapy                                                    521                                28                          Platinum-based         III         RCT                                     Advanced Urothelial Carcinoma (UC)
  10        Rittmeyer et al. ([@B23])      Atezolizumab    PD-L1           Atezolizumab vs. Docetaxel                                                        1187                               89                          Platinum based         III         RCT                                     Squamous or non squamous NSCLC
  11        Ferris et al. ([@B24])         Nivolumab       PD-1            Nivolumab vs. (Methotrexate, Docetaxel, or Cetuximab)                             347                                8                           Platinum-based         III         RCT                                     Recurrent Squamous-Cell Carcinoma of the Head and Neck
  12        Antonia et al. ([@B25])        Nivolumab       PD-1            Nivolumab vs. Nivolumab + Ipilimumab                                              213                                1                           Platinum-based         I/II        N/A                                     Recurrent SCLC
  13        Fehrenbacher et al. ([@B26])   Atezolizumab    PD-L1           Atezolizumab vs. Doctaxel                                                         277                                16                          Platinum-based         II          RCT                                     NSCLC
  14        Herbst et al. ([@B27])         Pembrolizumab   PD-1            Pembrolizumab vs. Docetaxel                                                       991                                33                          Platinum-containing    II/III      RCT                                     Advanced NSCLC
  15        Borghaei et al. ([@B28])       Nivolumab       PD-1            Nivolumab vs. Docetaxel                                                           555                                28                          Platinum-based         III         RCT                                     Non-squamous NSCLC
  16        Brahmer et al. ([@B29])        Nivolumab       PD-1            Nivolumab vs. Docetaxel                                                           260                                16                          Platinum-based         III         RCT                                     Squamous NSCLC
  17        Mok et al. ([@B30])            Pembrolizumab   PD-1            Pembrolizumab vs. Chemotherapy                                                    1,241                              51                          NO                     III         RCT                                     NSCLC

*RCT, Randomized controlled trial; BCP, Bevacizumab plus Carboplatin plus Paclitaxel; NSCLC, Non-Small Cell Lung Cancer; PD-1, Programmed Cell Death 1; PD-L1, Programmed Cell Death Ligand 1; SCLC, Small Cell Lung Cancer; CP, Carboplatin plus Paclitaxel; PC, Pemetrexed plus a platinum-based drug; Chemotherapy, Carboplatin plus Pemetrexed, Cisplatin plus Pemetrexed, Carboplatin plus Gemcitabine, Cisplatin plus Gemcitabine, or Carboplatin plus Paclitaxel; N/A, No Available*.

Assessment of Study Quality and Publication Bias
------------------------------------------------

Funnel plot, Egger\'s test and Newcastle-Ottawa scale, proposed by the Cochrane Collaboration, were taken to evaluate the bias ([@B31]--[@B35]). Three investigators (Shuisheng Zhang, Yi Zhao, Qingshan Zhu) were appointed to check the quality of all studies. The results, including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting, would be summarized in a figure together.

Outcome and Exposure of Interest
--------------------------------

The study name, year, phase, tumor type, PD-1 and PD-L1 inhibitor regimen, previous therapy regimen, number of evaluable cases, and number of peripheral neuropathy events were extracted from every enrolled study. Both all-grade and grade 3--5 peripheral neuropathy data were taken into account for the final comprehensive meta-analysis.

Assessment of Heterogeneity and Statistical Analysis
----------------------------------------------------

Cochrane\'s Q statistic and the *I*^2^ statistic were taken into account for evaluating the heterogeneity among enrolled studies just as suggested by Moher et al. ([@B31]) and Higgins et al. ([@B36]). The grade of heterogeneity was calculated by the range of *I*^2^ values. Heterogeneity was considered low, moderate or high according to *I*^2^ values \<25%, 25--50%, and \>50%, respectively.

Odds ratio (OR) value was reported to be a much more conservative evaluation parameter and might be more inclined to reveal a safety signal, as the method by which an OR is calculated provided a point estimate farther from unity than that provided by a HR. Odds ratio (OR), and 95% confidence interval (CI) would be calculated by random effect (RE) ([@B37]). Risk Ratio (RR) and Risk Difference (RD) were also calculated as secondary reference indicators for a more detailed interpretation of the results. *P* \< 0.05 was considered to be of statistically significance. In order to clarify the correlation between peripheral neuropathy and PD-1/PD-L1 inhibitors, we performed a large number of subgroup analyses based on the type of tumor, the treatment regimen and the specific drug. The software of Review Manager 5.3 was used for data consolidation and analysis. Statistical tests were all two-sided.

Results {#s3}
=======

Literature Search Results
-------------------------

According to the searching principle set by our team, 505 related documents were retrieved on the PubMed website, and 58 related documents were found in other websites or published documents.

After screening and eligibility assessment, a total of 17 clinical trials involving 10,500 patients were selected for the final meta-analysis. The flow diagram of the meta-analysis was shown in [Figure 1](#F1){ref-type="fig"}, while the risk of bias summary was shown in [Supplemental Figure 1](#SM1){ref-type="supplementary-material"}. All clinical trials enrolled in the meta-analysis included at least one experimental group and one control group ([@B14]--[@B30]).

![Study flow diagram of inclusion.](fonc-09-00866-g0001){#F1}

Characteristics of Identified Trials
------------------------------------

The basic characteristics of all the enrolled clinical trials were summarized in [Table 1](#T1){ref-type="table"} ([@B14]--[@B30]). The involving PD-1/PD-L1 inhibitors were nivolumab (*n* = 4) ([@B24], [@B25], [@B28], [@B29]), pembrolizumab (*n* = 6) ([@B14], [@B18], [@B19], [@B22], [@B27], [@B30]), and atezolizumab (*n* = 7) ([@B15]--[@B17], [@B20], [@B21], [@B23], [@B26]). Of all the clinical trials included, 14 were phase III ([@B14]--[@B24], [@B28]--[@B30]), 1 was phase II ([@B26]), 1 was phase II/III ([@B27]), and 1 was phase I/II ([@B25]). The tumors involved in 17 clinical trials included lung cancer (*n* = 11) ([@B16]--[@B18], [@B21], [@B23], [@B25]--[@B30]), urothelial cancer (*n* = 2) ([@B20], [@B22]), breast cancer (*n* = 1) ([@B15]), head and neck carcinoma (*n* = 2) ([@B14], [@B24]), and advanced gastric or gastro-esophageal junction cancer (*n* = 1) ([@B19]). Of the 11 lung cancer-related clinical trials, nine were limited to non-small cell lung cancer (NSCLC) and two were limited to small cell lung cancer (SCLC) ([@B16], [@B25]). 16 clinical trials were reported to be randomized controlled trial (RCT) ([@B14]--[@B24], [@B26]--[@B30]), while the information of one clinical trial was unavailable ([@B25]). Twelve trials underwent previous platinum-based treatments before PD-1/PD-L1 inhibitors ([@B14], [@B19]--[@B29]), while PD-1/PD-L1 inhibitors were prescribed as the first line therapy regimens for the other five trials ([@B15]--[@B18], [@B30]). The drugs used in 10 clinical trials were PD-1 inhibitors ([@B14], [@B18], [@B19], [@B22], [@B24], [@B25], [@B28]--[@B30]), while PD-L1 inhibitors were just given for the other seven clinical trials ([@B15]--[@B17], [@B20], [@B21], [@B23], [@B26]).

Risk of Bias
------------

Study quality and risk of bias among enrolled studies were checked by Newcastle-Ottawa scale ([@B35]). Random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), and selective reporting (reporting bias) were assessed by three members of our team independently and summarized in [Supplemental Figure 1](#SM1){ref-type="supplementary-material"}. Publication bias, evaluated by Harbord\'s test ([@B31]), was displayed by funnel plots ([Supplemental Figures 2, 3, 5, 7, 9, 11](#SM1){ref-type="supplementary-material"}).

Incidence Risk of All-Grade Peripheral Neuropathy
-------------------------------------------------

All included clinical trials were divided into four groups according to different treatment options, and the specific groups were as follows: Group A (PD-1/PD-L1 vs. Mono-therapy) ([@B19], [@B21], [@B23], [@B26]--[@B29]), Group B (PD-1/PD-L1 vs. Chemotherapy) ([@B14], [@B20], [@B22], [@B24], [@B30]), Group C (PD-1/PD-L1+ Chemotherapy vs. Chemotherapy) ([@B15]--[@B18]), Group D (PD-1 vs. PD-1+ CTLA-4) ([@B25]). Each group was further divided into two subgroups depending on the respective specific drug and tumor type. Meta-analysis was not performed in group D, because only one group of clinical trials was enrolled, and only one patient in both subgroups was reported with peripheral neuropathy ([@B25]).

We first performed a meta-analysis on the data of Group A, and the results of the analysis were summarized at the bottom of [Figure 2A](#F2){ref-type="fig"} \[OR = 0.08, 95%CI:\[0.03, 0.19\], I^2^ = 69%, Z = 5.64 (*P* \< 0.00001)\] ([@B19], [@B21], [@B23], [@B26]--[@B29]). Subgroup analysis was performed according to the different drug types in the control group and the experimental group, and the results were shown in [Figures 2A1,A2](#F2){ref-type="fig"}, respectively. Moderate heterogeneity was found in Group A (*I*^2^ = 69%). Subgroup analysis results suggested that the source of heterogeneity was the PD-L1 subgroup \[[Figure 2A2](#F2){ref-type="fig"}; ([@B21], [@B23], [@B26])\]. The funnel plots of OR for Group A could be seen in [Supplemental Figures 2A1,A2](#SM1){ref-type="supplementary-material"}. Similar to the results of OR, RR and RD of Group A were displayed in [Supplemental Figures 4A, 6A](#SM1){ref-type="supplementary-material"}.The corresponding funnel plots were gathered in [Supplemental Figures 5A, 7A](#SM1){ref-type="supplementary-material"}.

![Forest plots for the odds ratio of treatment related peripheral neuropathy for all grade. **(A1)** Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 vs. Docetaxel/Paclitaxel). Subgroup analysis was performed according to the type of chemotherapy drug in the control group. **(A2)** Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 vs. monotherapy). Subgroup analysis was performed based on the drug type (PD-1 or PD-L1) of the experimental group. **(B1)** Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 vs. Chemotherapy). Subgroup analysis was performed based on the drug type (PD-1 or PD-L1) of the experimental group. **(B2)** Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 vs. Chemotherapy). Subgroup analysis was performed based on the specific types of tumors in the experimental and control groups. **(C1)** Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 + Chemotherapy vs. Chemotherapy). Subgroup analysis was performed based on the drug type (PD-1 or PD-L1) of the experimental group. **(C2)** Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 + Chemotherapy vs. Chemotherapy). Subgroup analysis was performed based on the specific types of tumors in the experimental and control groups.](fonc-09-00866-g0002){#F2}

When PD-1/PD-L1 drugs were compared with chemotherapy (Group B), the incidence of peripheral neuropathy was significantly lower than that of the control group, and the OR results are summarized in [Figure 2B](#F2){ref-type="fig"} \[OR = 0.05, 95%CI:\[0.03, 0.11\], I^2^ = 0%, Z = 7.68 (*P* \< 0.00001)\] ([@B14], [@B20], [@B22], [@B24], [@B30]). The funnel plots of OR for Group B could be seen in [Supplemental Figures 2B1,B2](#SM1){ref-type="supplementary-material"}. The subgroup analysis results were also similar to the subgroup analysis results of group A. RR and RD of Group B were displayed in [Supplemental Figures 4B, 6B](#SM1){ref-type="supplementary-material"}.The corresponding funnel plots were gathered in [Supplemental Figures 5B, 7B](#SM1){ref-type="supplementary-material"}. No obvious heterogeneity was found among Group B (*I*^2^ = 0%).

Different from the met-analysis results of group A and group B, we found that the analysis results of OR were not statistically significant when performing meta-analysis on Group C ([Figure 2C](#F2){ref-type="fig"}) \[OR = 1.22, 95%CI:\[1.00, 1.49\], *I*^2^ = 4%, *Z* = 1.99 (*P* = 0.05)\] ([@B15]--[@B18]). The same trend could be seen in the results of RD ([Supplemental Figure 6C](#SM1){ref-type="supplementary-material"}) \[RD = 0.03, 95%CI:\[0.01, 0.06\], *I*^2^ = 47%, *Z* = 1.42(*P* = 0.16)\] ([@B15]--[@B18]). The corresponding funnel plots of them were gathered in [Supplemental Figures 2C, 7C](#SM1){ref-type="supplementary-material"}. The RR of Group C showed that the incidence risk of peripheral neuropathy in the PD-1/PD-L1 combined chemotherapy subgroup was significantly higher than that in the chemotherapy subgroup, and the *P*-value was statistically significant ([Supplemental Figure 4C](#SM1){ref-type="supplementary-material"}) \[RR = 1.16, 95%CI:\[1.01, 1.34\], *I*^2^ = 0%, *Z* = 2.13(*P* = 0.03)\] ([@B15]--[@B18]). The corresponding funnel plots of RR were gathered in [Supplemental Figure 5C](#SM1){ref-type="supplementary-material"}. No obvious heterogeneity was found among Group C (*I*^2^ = 0%).

Incidence Risk of Grade 3--5 Peripheral Neuropathy
--------------------------------------------------

Twelve clinical trials with the information of grade 3--5 peripheral neuropathy were taken into account for further meta-analysis ([@B15]--[@B20], [@B22], [@B23], [@B27]--[@B30]). The same grouping and subgroup approach as before were taken for dealing with them. In the experimental subgroup of Group A and Group B, using PD-1/PD-L1 inhibitors alone, the incidence rate of peripheral neuropathy was 0% ([@B19], [@B20], [@B22], [@B23], [@B27]--[@B30]). In other words, in patients with solid tumors treated with PD-1/PD-L1 alone, the incidence rate of grade 3--5 peripheral neuropathy was 0% ([@B19], [@B20], [@B22], [@B23], [@B25], [@B27]--[@B30]).

In Group A, the incidence risk of PD-1/PD-L1 subgroup was obvious lower than the control group \[OR = 0.13, 95%CI:\[0.04, 0.45\], *I*^2^ = 0%, *Z* = 3.24 (*p* = 0.001); [Figure 3A](#F3){ref-type="fig"}; ([@B19], [@B23], [@B27]--[@B29])\]. Different grouping methods for subgroup analysis were adopted for dealing with all the data, no statistically significant difference was found among them ([Figures 3A1,A2](#F3){ref-type="fig"}). No heterogeneity was found in Group A (*I*^2^ = 0%). Similar to the results of OR, RR, and RD of Group A were displayed in [Supplemental Figures 8A, 10A](#SM1){ref-type="supplementary-material"}. The corresponding funnel plots were summarized in [Supplemental Figures 9A, 11A](#SM1){ref-type="supplementary-material"}.

![Forest plots for the odds ratio of treatment related peripheral neuropathy for grade 3--5. **(A1)** Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 vs. Docetaxel/Paclitaxel). Subgroup analysis was performed based on the specific types of tumors in the experimental and control groups. **(A2)** Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 vs. monotherapy). Subgroup analysis was performed based on the drug type (PD-1 or PD-L1) of the experimental group. **(B1)** Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 vs. Chemotherapy). Subgroup analysis was performed based on the drug type (PD-1 or PD-L1) of the experimental group. **(B2)** Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 vs. Chemotherapy). Subgroup analysis was performed based on the specific types of tumors in the experimental and control groups. **(C1)** Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 + Chemotherapy vs. Chemotherapy). Subgroup analysis was performed based on the drug type (PD-1 or PD-L1) of the experimental group. **(C2)** Forest plots for the odds ratio of treatment related peripheral neuropathy (PD-1/PD-L1 + Chemotherapy vs. Chemotherapy). Subgroup analysis was performed based on the specific types of tumors in the experimental and control groups.](fonc-09-00866-g0003){#F3}

When PD-1/PD-L1 drugs were compared with chemotherapy (Group B), the incidence risk of peripheral neuropathy limited to grade 3--5 was significantly lower than that of the control group, and the OR results are summarized in [Figure 3B](#F3){ref-type="fig"} \[OR = 0.11, 95%CI:\[0.03, 0.49\], *I*^2^ = 0%, Z = 2.92 (*P* = 0.004)\] ([@B20], [@B22], [@B30]). The funnel plots of OR for Group B could be seen in [Supplemental Figures 3B1,B2](#SM1){ref-type="supplementary-material"}. Similar to the results of OR, RR, and RD of Group B were displayed in [Supplemental Figures 8B, 10B](#SM1){ref-type="supplementary-material"}.The corresponding funnel plots were gathered in [Supplemental Figures 9B, 11B](#SM1){ref-type="supplementary-material"}. No heterogeneity was found in Group B (*I*^2^ = 0%) ([@B20], [@B22], [@B30]).

The OR of Group C showed that the incidence risk of peripheral neuropathy in the PD-1/PD-L1 combined chemotherapy subgroup was significantly higher than that in the chemotherapy subgroup, and the *P*-value was statistically significant ([Figure 3C](#F3){ref-type="fig"}) \[OR = 1.74, 95%CI:\[1.03, 2.92\], *I*^2^ = 0%, *Z* = 2.09 (*P* = 0.04)\] ([@B15]--[@B18]). The corresponding funnel plots of OR were gathered in [Supplemental Figure 3C](#SM1){ref-type="supplementary-material"}. No heterogeneity was found in Group C (*I*^2^ = 0%). Similar analysis results could also be seen in [Supplemental Figure 8C](#SM1){ref-type="supplementary-material"}, when the data of Group C was evaluated by RR \[RR = 1.71, 95%CI:\[1.03, 2.83\], *I*^2^ = 0%, Z = 2.09 (*P* = 0.04)\]. Different from OR and RR, the meta-analysis result was of no statistical significance ([Supplemental Figure 10](#SM1){ref-type="supplementary-material"}), when it was calculated by RD \[RD = 0.01, 95%CI:\[0.00, 0.02\], I^2^ = 10%, Z = 1.82 (*P* = 0.07)\]. The corresponding funnel plots of RD were gathered in [Supplemental Figure 11C](#SM1){ref-type="supplementary-material"}. Low heterogeneity related to RD was found in Group C (*I*^2^ = 10%). Subgroup analysis revealed that the source of heterogeneity might be related to the inclusion of this clinical trial ([@B15]).

Discussion {#s4}
==========

Peripheral neuropathy is a painful condition deriving from many and varied etiologies ([@B38], [@B39]). Certain medications have been implicated in the iatrogenic development of drug induced peripheral neuropathy (DIPN) and include chemotherapeutic agents, antimicrobials, cardiovascular drugs, psychotropic, anticonvulsants, among others ([@B39]). Chemotherapy-induced peripheral neuropathy (CIPN), reported in several studies, especially for paclitaxel induced peripheral neuropathy, was common for cancer patients ([@B40], [@B41]). CIPN was a dose limiting toxicity, negatively impacting both quality of life and disease outcomes ([@B42]). However, during the process of anti-tumor treatment, combinations of drugs that were unknown to cause CIPN were prescribed for cancer patients, and sequential treatment for recurrence with additional CIPN-inducing drugs would also be suggested ([@B43]). Therefore, it would be difficult for us to determine which specific drug was responsible for the occurrence of peripheral neuropathy, especially for some newly marketed targeted anti-tumor drugs without fully understanding of toxicities, such as PD-1/PD-L1 inhibitors and Brentuximab vedotin ([@B3], [@B14]--[@B30]). To clarify the association between incidence risk of peripheral neuropathy and PD-1/PD-L1 inhibitors, we designed this meta-analysis.

After screening and eligibility assessment, a total of 17 clinical trials involving 10,500 patients were selected for the final meta-analysis. The flow diagram of the meta-analysis was shown in [Figure 1](#F1){ref-type="fig"}, while the risk of bias summary was shown in [Supplemental Figure 1](#SM1){ref-type="supplementary-material"}. All clinical trials enrolled in the meta-analysis included at least one experimental group and one control group ([@B14]--[@B30]). Study quality and risk of bias among enrolled studies were checked by Newcastle-Ottawa scale ([@B35]). All clinical trials included were considered to be of higher quality. Therefore, the analytical conclusions based on the data of these clinical trials could represent certain reliability, authenticity, and credibility ([@B14]--[@B30]). In this study, we tried as many subgroup analysis methods as possible, and conducted a systematic and comprehensive analysis of the results, so the analysis results obtained were much more accurate ([Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} and [Supplemental Figures 4, 6, 8, 10](#SM1){ref-type="supplementary-material"}) than that was analyzed just by one model.

The incidence of peripheral neuropathy for all grade was significantly lower in the PD-1/PD-L1 inhibitor group than that of the control group, either monotherapy (OR = 0.08, 95%CI:\[0.03, 0.19\], [Figure 2A](#F2){ref-type="fig"}) or chemotherapy (OR = 0.05, 95%CI:\[0.03, 0.11\], [Figure 2B](#F2){ref-type="fig"}) ([@B14], [@B19]--[@B24], [@B26]--[@B30]). Moderate heterogeneity was found in Group A (*I*^2^ = 69%) but Group B (*I*^2^ = 0%). Subgroup analysis results suggested that the source of heterogeneity was the PD-L1 subgroup ([Figure 2A2](#F2){ref-type="fig"}) ([@B21], [@B23], [@B26]). The funnel plots of OR for Group A could be seen in [Supplemental Figures 2A1,A2](#SM1){ref-type="supplementary-material"}. Similar to the results of OR, Forest plots of RR and RD for Group A were displayed in [Supplemental Figures 4A, 6A](#SM1){ref-type="supplementary-material"}. The corresponding funnel plots were summarized in [Supplemental Figures 5A, 7A](#SM1){ref-type="supplementary-material"}. We found the existence of asymmetry of the funnel plot of Group A analysis ([@B19], [@B21], [@B23], [@B26]--[@B29]), so we concluded that there might be publication bias, but we could not rule out the possibility of asymmetry caused by other factors. Similar incidence risk of peripheral neuropathy for grade 3--5 could also be seen in [Figure 3A](#F3){ref-type="fig"} (OR = 0.13, 95%CI:\[0.04, 0.45\]) ([@B19], [@B23], [@B27]--[@B29]). However, the heterogeneity (*I*^2^ = 0%) and the asymmetry of the funnel chart were not found \[[Supplemental Figure 3A](#SM1){ref-type="supplementary-material"}; ([@B19], [@B23], [@B27]--[@B29])\]. Based on the above analysis results, we concluded that the heterogeneity and the asymmetry of the funnel plot were mainly derived from those two clinical trials ([@B21], [@B26]).

When PD-1/PD-L1 inhibitors were used in combination with chemotherapy (Group C), the risk of peripheral neuropathy was higher than in the control chemotherapy group, whether it was all-grade (OR = 1.22, 95%CI:\[1.00, 1.49\], [Figure 2C](#F2){ref-type="fig"}) or grade 3--5 degree (OR = 1.74, 95%CI:\[1.03, 2.92\], [Figure 3C](#F3){ref-type="fig"}) ([@B15]--[@B18]). Similar incidence trend could also be obtained when they were evaluated by RR ([Supplemental Figures 4C, 8C](#SM1){ref-type="supplementary-material"}). No obviously statistical significant results of RD were only seen in [Supplemental Figures 6C, 8C](#SM1){ref-type="supplementary-material"}. Obvious heterogeneity and the asymmetry of the funnel chart were not found in Group C ([Supplemental Figures 2C, 3C, 5C, 7C, 9C, 11C](#SM1){ref-type="supplementary-material"}). It proved that the analytical conclusions we had obtained were credible.

A lot of clinical trials had reported that PD-1/PD-L1 inhibitors had better safety and satisfactory clinical efficacy in the process of anti-tumor therapy ([@B14]--[@B30], [@B44]). In the experimental subgroup of Group A and Group B, using PD-1/PD-L1 inhibitors alone, the incidence rate of peripheral neuropathy for grade 3--5 was 0% ([@B19], [@B20], [@B22], [@B23], [@B27]--[@B30]). In other words, if we encounter peripheral neuropathy of grade 3--5 in the course of anti-tumor therapy, the possibility caused by the PD-1/PD-L1 inhibitor was firstly excluded. Chemotherapy-induced peripheral neuropathy (CIPN), reported in several studies, especially for paclitaxel induced peripheral neuropathy, was common for cancer patients ([@B40], [@B41]). Stopping the use of related drugs remained to be the primary principle for the treatment of drug-related peripheral neuropathy. However, stopping all anti-tumor treatment for cancer patients, especially for advanced cancer patients, might lead to rapid progression of the tumor, and even endanger the patient\'s life. Based on the results of our analysis, we found that PD-1/PD-L1 inhibitors often played a secondary role for patients suffering from severe drug-related peripheral neuropathy \[[Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}; ([@B14]--[@B30])\]. Therefore, when it was necessary to stop anti-tumor therapy to alleviate severe peripheral neuropathy in patients, chemotherapy drugs other than PD-1/PD-L1 would be considered first ([Figures 2C](#F2){ref-type="fig"}, [3C](#F3){ref-type="fig"}) ([@B15]--[@B18]). This finding had an important clinical guiding significance in clinical work.

Conclusions {#s5}
===========

Compared with chemotherapy, incidence risk of peripheral neuropathy related to PD-1/PD-L1 inhibitor was significantly lower than that of the chemotherapy group, while PD-1/PD-L1 inhibitor increased the incidence risk of peripheral neuropathy when it was combined with chemotherapy.
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CI

:   confidence interval

CIPN

:   Chemotherapy-induced peripheral neuropathy

DIPN

:   drug induced peripheral neuropathy

FE

:   fixed effect

HR

:   hazard ratios

OR

:   odds ratio

PD-1

:   programmed cell death-1

PD-L1

:   programmed cell death ligand 1

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

RD

:   risk difference

RE

:   random effect

RR

:   risk ratio.
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